Drug Trial Radar · NCT01367665
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Jun 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,232
Actual
Start
Jul 1, 2011
Primary completion
Jun 14, 2017
Study completion Jun 14, 2017
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 7, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Patients will receive oral doses of vismodegib 150 mg once daily until disease progression or unacceptable toxicity.
Conditions
- Basal Cell Carcinoma
Interventions
vismodegibDrug
150 mg once daily until disease progression or unacceptable toxicity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs)Time frame: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
- Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other ReasonsTime frame: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
- Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory ParametersTime frame: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
- Exposure to Study Treatment: Duration on TreatmentTime frame: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
- Exposure to Study Treatment - Dose IntensityTime frame: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Locations
181 sites in 37 countries. Site status is shown where the registry gives one.
Inst. de Oncologia Angel H. Roffo ; Servicio de Oncologia
Buenos Aires, Argentina
Premier Specialists
Kogarah, New South Wales, Australia
Skin and Cancer Foundation Australia
Westmead, New South Wales, Australia
CMAX A division of IDT Australia Limited
Adelaide, South Australia, Australia
Skin & Cancer Foundation
Carlton, Victoria, Australia
LKH Graz; Abteilung für allgemeine Dermatologie
Graz, Austria
LKH Salzburg; Universitätsklinik für Dermatologie
Salzburg, Austria
Landesklinikum St. Pölten
Sankt Pölten, Austria
Medizinische Universität Wien; Univ.Klinik für Dermatologie
Vienna, Austria
UZ Leuven Gasthuisberg
Leuven, Belgium
University Clinical Center of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina
Clinic of Oncology, University Clinical Center Sarajevo
Sarajevo, Bosnia and Herzegovina
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
District Oncology Dispensary; Department for Oncology and Dermatology
Plovdiv, Bulgaria
National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic
Sofia, Bulgaria
Centre de Recherche Dermatologique du Quebec Metropolitain (CRDQ)
Québec, Canada
Western Canada Dermatology Institute
Edmonton, Alberta, Canada
Cancer Care Manitoba
Winnipeg, Manitoba, Canada
London Regional Cancer Centre
London, Ontario, Canada
Dr. Nowell Solish Cosmetic Dermatology
Toronto, Ontario, Canada
Victoria Park MediSpa
Montreal, Quebec, Canada
Inst. Nacional de Cancerologia; Clinica de Seno
Bogotá, Colombia
Riesgo De Fractura; Rheumatology
Bogotá, Colombia
Hemato Oncologos S.A.
Cali, Colombia
Reumalab Sas; Rheumatology
Medellín, Colombia
Hospital Pablo Tobon Uribe
Medellin-Antioquia, Colombia
Clinical Hospital Sisters of Mercy
Zagreb, Croatia
Nemocnice Ceske Budejovice
České Budějovice, Czechia
Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology
Hradec Králové, Czechia
Fakultní nemocnice Ostrava; Kožní oddělení
Ostrava, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni
Prague, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Herlev Hospital; Onkologisk afdeling
Herlev, Denmark
Helsinki University Central Hospital; Skin & Allergy Hospital
Helsinki, Finland
Kuopion yliopistollinen sairaala
Kuopio, Finland
Hopital Saint Andre CHU De Bordeaux; Dermatologie
Bordeaux, France
Showing 40 of 181 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.